Table 5 Breast cancer diagnoses by year and receptor-based subtype, SEER 17 registries, 2018–2021

From: Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021

  

HR+/HER2−

HR+/HER2+ 

TNBC

HR−/HER2+ 

Total

 

Year

N

N

N

N

N

N2-3M0(Any T)

2018

2101

328

380

136

2945

 

2019

2264

298

403

128

3093

 

2020

1994

311

354

112

2771

 

2021

2156

260

379

123

2918

T3-4N0-1M0

2018

2007

419

480

242

3148

 

2019

2168

407

516

238

3329

 

2020

2051

455

550

219

3275

 

2021

2320

446

632

312

3710

  1. HER2 human epidermal growth factor receptor-2, HR hormone receptor; TNBC triple negative breast cancer.
Back to article page